RCUS Arcus Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RCUS

Price (delayed)

$26.39

Market cap

$3.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.91

Enterprise value

$3.31B

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 25

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies.

Highlights
RCUS's revenue has shrunk by 55% YoY and by 50% QoQ
The gross profit has plunged by 55% YoY and by 50% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcusbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RCUS

RCUS stock price

How has the Arcus Biosciences stock price performed over time
Intraday
-1.79%
1 week
7.06%
1 month
-13.02%
1 year
112.99%
YTD
10.74%
QTD
-14.4%

Financial performance

How have Arcus Biosciences's revenue and profit performed over time
Revenue
$117M
Gross profit
$117M
Operating income
-$486M
Net income
-$460M
Gross margin
100%
Net margin
-393.2%
Arcus Biosciences's net margin has plunged by 151% from the previous quarter
The operating margin has dropped by 146% since the previous quarter
RCUS's revenue has shrunk by 55% YoY and by 50% QoQ
The gross profit has plunged by 55% YoY and by 50% from the previous quarter

Price vs fundamentals

How does RCUS's price correlate with its fundamentals

Growth

What is Arcus Biosciences's growth rate over time

Valuation

What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
7.15
P/S
28.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.3
RCUS's EPS is down by 23% year-on-year and by 23% since the previous quarter
RCUS's price to book (P/B) is 135% higher than its 5-year quarterly average of 3.1 and 40% higher than its last 4 quarters average of 5.2
RCUS's equity is down by 15% year-on-year and by 11% since the previous quarter
RCUS's P/S is 143% above its 5-year quarterly average of 11.9 and 89% above its last 4 quarters average of 15.3
RCUS's revenue has shrunk by 55% YoY and by 50% QoQ

Efficiency

How efficient is Arcus Biosciences business performance
RCUS's return on sales has dropped by 152% since the previous quarter
RCUS's ROIC has plunged by 82% YoY and by 27% from the previous quarter
Arcus Biosciences's return on assets has shrunk by 77% YoY and by 29% QoQ
The return on equity has dropped by 60% year-on-year and by 30% since the previous quarter

Dividends

What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCUS.

Financial health

How did Arcus Biosciences financials performed over time
The total assets is 101% greater than the total liabilities
RCUS's quick ratio is down by 15% year-on-year and by 6% since the previous quarter
RCUS's current ratio is down by 15% YoY and by 5% from the previous quarter
Arcus Biosciences's debt is 78% less than its equity
RCUS's debt to equity is up by 22% year-on-year and by 16% since the previous quarter
RCUS's equity is down by 15% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.